DENVER, CO--(Marketwired - Jul 6, 2016) - American Cannabis Company, Inc. (OTCQB: AMMJ) (the "Company"), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has secured a consulting contract in State of California. This marks the company's first client in the state of California, bringing their current market reach to 17 states as well as Canada and Guam.

The contract focuses on ACC's business planning and application services to support their client's effort to secure a license under California's Medical Marijuana Safety and Regulation Act. ACC expects to leverage this contract to secure additional revenues through long-term consulting agreements, potential sales of ancillary products and services to aid cultivation as well as dispensary operations.

Corey Hollister, president and CEO, American Cannabis Company, commented: "We are excited to bring the deep experience we have gained in establishing and operating in fully regulated markets to California, the birthplace of modern medical cannabis in America. California remains the largest cannabis market and presents significant opportunities for operators looking to participate in the next phase of its development."

About American Cannabis Company, Inc.:
American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and operational best practices. Through our two vertically integrated businesses, American Cannabis Consulting and American Cultivator Company, a group purchasing organization, we support our clients from concept to creation to commercialization to on-going operations.

For more information, please visit: www.americancannabiscompanyinc.com.

Forward Looking Statements

This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.